LITTLE KNOWN FACTS ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS.

Participant consumed grapefruit or grapefruit merchandise within 3 times ahead of the main dose of study drug.- "Our study uncovered the important purpose of your KLF16/MYC regulatory axis in modulating tumor expansion and chemotherapy sensitivity in BLCA, suggesting that combining bromodomain inhibitors, for instance OTX015 or ABBV-744, with DDP o